

SURVEILLANCE

COVID-19 vaccination coverage in the EU/EEA during the 2024–25 season campaigns

1 August 2024 to 28 March 2025

Key facts

- This report presents a description of COVID-19 vaccine coverage in the European Union/European Economic Area (EU/EEA) between 1 August 2024 and 28 March 2025.
- During the reporting period, 21 out of 30 EU/EEA countries reported data on COVID-19 vaccination coverage for at least one group (people aged 60 years and above, people aged 80 years and above, healthcare workers, people with chronic conditions, pregnant women).
- During this period, approximately 13.6 million people aged 60 years and above received one COVID-19 vaccine dose. Of these, approximately four million people were aged 80 years and above.
- The median COVID-19 vaccination coverage among people aged 60 years and above was 8.7% (range: <0.1–52.8%), with high variation among countries. For people aged 80 years and above, the median coverage was 8.5% (range: 0.9–83.5%), with high variation among countries.
- Among the 21 reporting countries, one country reported a vaccination coverage $\geq 50\%$ for the age group 60 years and above, while seven countries reported a vaccination coverage $\geq 50\%$ for the age group 80 years and above. The number of countries increased to eight for those reporting a vaccination coverage of $> 30\%$ for the age group 60 years and above, and to nine for the age group 80 years and above.
- Most of the approximately 15.5 million COVID-19 vaccine doses administered in the EU/EEA during this period in the overall population were the Pfizer BioNTech – Comirnaty JN.1 vaccine (around 11.3 million doses; 73.3% of the total doses administered).

Introduction

This report presents a description of COVID-19 vaccine coverage in the EU/EEA between 1 August 2024 and 28 March 2025, with some variation in dates between countries.

In this report, COVID-19 vaccine coverage is defined as the percentage of the target population group that has received one dose of a COVID-19 vaccine during the reporting period. It represents the number of individuals in the total target group who received one vaccine dose during the period under analysis.

Suggested citation: European Centre for Disease Prevention and Control. COVID-19 vaccination coverage in the EU/EEA during the 2024–25 season campaigns, 1 August 2024 – 28 March 2025. Stockholm: ECDC; 2025.

ISBN: 978-92-9498-779-2

doi: 10.2900/2239152

Catalogue number: TQ-01-25-010-EN-N

Stockholm, June 2025

Since the start of COVID-19 vaccination campaigns in December 2020, ECDC has regularly collected and presented data on COVID-19 vaccine uptake in the EU/EEA through a [dynamic dashboard](#) and [open data files](#). Since September 2023, when COVID-19 vaccination started to be implemented in the majority of EU/EEA countries mostly with campaigns focusing on the autumn, ECDC has updated its COVID-19 vaccination coverage data analysis process and the related reports.

Methods

From 1 August 2024 to 28 March 2025, data were collected to describe vaccination coverage in the EU/EEA during the 2024–25 season. In particular, data were collected on vaccine doses administered in population groups targeted by national vaccination programmes, regardless of an individual's previous immunisation status.

The methodology used for calculation was the number of doses administered per target group (numerator), divided by the number of individuals in the target group (denominator) multiplied by 100. Denominators for age-specific target groups were obtained from Eurostat, as of 2023 (extracted in August 2024). Denominators used for the groups healthcare workers, individuals with chronic illness and pregnant women were reported to ECDC (The European Surveillance System, TESSy) by each country, when available.

Results

During the reporting period, 21 out of 30 EU/EEA countries reported on COVID-19 vaccination coverage for at least one target group (people aged 60 years and above, people aged 80 years and above, healthcare workers, people with chronic conditions, pregnant women). Data completeness for different target groups differed substantially across countries.

For the age group 60 years and above, approximately 13.6 million people received a dose of COVID-19 vaccine. The median coverage among people in this age group was 8.7% (range: <0.1–52.8%), with high variation across countries (Table 1 and Figure 1). Among the 21 countries reporting data for this target group, none reported a coverage $\geq 80\%$.

For the age group 80 years and above, approximately four million people received a dose of COVID-19 vaccine. The median coverage among people in this age group was 8.5% (range: 0.9–83.5), with high variation across countries (Table 1 and Figure 2). Among the 21 countries reporting data for this target group, only one country reported a coverage $\geq 80\%$ (Sweden 83.5%).

Table 1. COVID-19 vaccine coverage in target age groups, 21 EU/EEA countries, 1 August 2024 to 28 March 2025

Age group	Median coverage in the EU/EEA ^a (range)	Number of countries with $\geq 80\%$ coverage	Number of countries with $\geq 50\%$ coverage	Number of countries with $\geq 30\%$ coverage
60+ years	8.73% (<0.1–52.8%)	0/21	1/21	8/21
80+ years	8.5% (0.9–83.5)	1/21	7/21	9/21

^a Values are the median across all the reporting countries for one dose received. The reporting period may be different for some countries, as indicated in Table 2.

Figure 1. COVID-19 vaccine coverage among people aged 60 years and above, 21 EU/EEA countries, 1 August 2024 to 28 March 2025





Figure 2. COVID-19 vaccine coverage among people aged 80 years and above, 21 EU/EEA countries, 1 August 2024 to 28 March 2025



Among the 21 countries reporting data, six countries reported data disaggregated by at least one of the following target groups: healthcare workers, individuals with chronic conditions, or pregnant women (Table 2). Healthcare workers were defined as those who work in healthcare settings who may come into contact with patients, including administrative staff and home care staff. Individuals with chronic conditions included any person aged between 18–59 years with at least one underlying medical condition and a recommendation for COVID-19 vaccination. Pregnant women were defined as any pregnant individual during any trimester.

Among the six countries that reported disaggregated data for healthcare workers, the highest vaccination coverage was observed in Belgium (13.7%). Two countries reported disaggregated data for individuals with chronic conditions, with the highest coverage observed in Spain (4%). Two countries reported disaggregated data for pregnant women, with the highest coverage observed in Ireland (6.9%).

Table 2. COVID-19 vaccine coverage by target group, 21 EU/EEA countries, 1 August 2024 to 28 March 2025

Country	Aged 60–69 years ^a	Aged 70–79 years	Aged 80 years and above	Healthcare workers	People with chronic conditions	Pregnant women	Period reported
Belgium ^a	12.6%	43.6%	47.4%	13.7%	NDR	NDR	Aug 24 – Feb 25
Bulgaria	0.4%	2.1%	2.0%	0.6%	NDR	NDR	Aug 24 – Dec 24
Cyprus	0.7%	3.6%	4.5%	NDR	NDR	NDR	Aug 24 – Mar 25
Czechia	2.3%	10.7%	13.6%	6.0%	1.8%	NDR	Aug 24 – Feb 25
Denmark ^a	12.8%	59.8%	64.1%	NDR	NDR	NDR	Aug 24 – Oct 24
Estonia	2.8%	15.3%	8.5%	NDR	NDR	NDR	Aug 24 – Dec 24
Finland ^a	11.9%	60.3%	69.7%	NDR	NDR	NDR	Aug 24 – Feb 25
Greece	0.5%	1.7%	1.4%	1.2%	NDR	NDR	Aug 24 – Feb 25
Hungary	0.1%	0.6%	0.9%	NDR	NDR	NDR	Aug 24 – Feb 25
Ireland	13.2%	46.1%	61.8%	9.2%	NDR	6.9%	Aug 24 – Feb 25
Italy	1.1%	4.8%	7.0%	NDR	NDR	NDR	Sep 24 – Mar 25
Latvia ^a	1.3%	5.2%	5.8%	NDR	NDR	NDR	Aug 24 – Feb 25
Lithuania ^a	0.5%	1.8%	2.3%	NDR	NDR	NDR	Aug 24 – Feb 25
Luxembourg	0.8%	2.8%	4.9%	NDR	NDR	NDR	Aug 24 – Feb 25
Netherlands ^b	16.5%	58.8%	63.3%	NDR	NDR	NDR	Aug 24 – Jan 25
Norway ^a	12.1%	55.1%	60.1%	NDR	NDR	NDR	Aug 24 – Feb 25
Poland	1.2%	5.6%	4.2%	NDR	NDR	NDR	Aug 24 – Feb 25
Portugal	13.6%	46.6%	56.4%	NDR	NDR	NDR	Aug 24 – Mar 25
Slovenia ^a	0.7%	3.0%	4.3%	NDR	NDR	NDR	Aug 24 – Feb 25
Spain	7.3%	27.3%	36.9%	6.1%	4.0%	5.7%	Aug 24 – Mar 25
Sweden	11.6%	62.2%	83.5%	NDR	NDR	NDR	Aug 24 – Nov 24

NDR: no data reported.

^a In some reporting countries, the COVID-19 vaccine was only recommended in people aged 65 years and above (Belgium, Denmark, Finland, Norway, Slovenia, Lithuania, Latvia, and possibly others). Therefore, the vaccination coverage in this age group (60–69 years) needs to be interpreted with caution.

^b In the Netherlands, each individual receiving a COVID-19 dose must provide informed consent to the healthcare provider in order for their non-anonymous vaccination data to be shared with the national authorities. Doses administered to people who have since died or emigrated are not included in the reported number of individual doses. Therefore, data for this country need to be interpreted with caution, as they could underestimate the actual number of doses administered nationwide.

Across the 21 reporting countries, approximately 15.5 million COVID-19 vaccine doses have been administered during the reporting period among the total population (Table 3). Around 11 million doses (73.3% of the total doses administered) were the Pfizer BioNTech – Comirnaty JN.1 vaccine.

Around 981 000 doses (6.3% of the total doses administered) were the Pfizer BioNTech – Comirnaty KP.2 vaccine and approximately 505 000 doses (3.3% of the total doses administered) were the Moderna - Spikevax JN.1 vaccine. Approximately 1 871 000 doses (12.1% of the total doses administered) were reported as 'other vaccine product'. The remaining administered doses (approximately 764 000 doses, representing the 4.9% of the total doses administered) were reported as 'unknown vaccine product'.

Table 3. COVID-19 doses administered to people aged 18 years and above, by vaccine product, 21 EU/EEA countries, 1 August 2024 to 28 March 2025

Vaccine product (manufacturer – product name)	Number of doses administered	Percentage of the total number of doses administered
Pfizer BioNTech – Comirnaty KP.2	981309	6.3 %
Pfizer BioNTech – Comirnaty JN.1	11335627	73.3%
Moderna – Spikevax JN.1	505723	3.3%
Other vaccine product ^a	1871615	12.1%
Unknown vaccine product	763946	4.9%
All doses	15458220	NA

NA: not applicable.

^a Includes any other vaccine products targeting COVID-19 that were administered in the EU/EEA during the period under analysis.

Limitations

These results must be interpreted with caution. This includes making comparisons across countries or analysis of any indicator aiming to describe the coverage in the EU/EEA as a whole. As the vaccination campaigns are ongoing, all possible factors should be considered, including data completeness and quality.

Resources

ECDC has also created the following resources on this topic:

- [European Respiratory Virus Surveillance Summary dashboard](#): Overview of respiratory virus epidemiology in the EU/EEA through an interactive dashboard of selected indicators.
- [ECDC vaccine tracker](#): Historic data of selected indicators through an interactive dashboard covering week 50, 2020 to week 39, 2023.
- [ECDC open data files on COVID-19 vaccination in the EU/EEA](#): Downloadable files with all historic row data available, covering week 50, 2020 to week 39, 2023. These files are intended for external users that are competent in data analysis.